Karyopharm Therapeutics price to sales ratio KPTI

Market value divided by revenue over the last twelve months, since 2019.

Today, Oct 23, 2026: 0.1×
7-year median: 1.6×
Against its 7-year history: 0th; percentile: 0 is its lowest day, 100 its highest
7-year range: 0.1× to 76.9×
Peer median: 0.9×

Karyopharm Therapeutics' price to sales ratio is 0.1× as of Oct 23, 2026.

That is below its 7-year median of 1.6×, lower than on 100% of days in the last 7 years.

Over that time it ranged from 0.1× in Oct 2026 to 76.9× in Nov 2019.

The median for 3 large drugmakers of a similar size is 0.9×.

Price to sales ratio over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	0.1×	0.1×	1.6×
2025	0.5×	0.2×	0.7×
2024	0.6×	0.5×	1.2×
2023	0.7×	0.6×	3.1×
2022	1.1×	0.8×	9.1×
2021	4.1×	3.4×	14.2×
2020	12.5×	11.4×	50.1×
2019	52.5×	13.8×	76.9×

Against its peers

Companies in Drug Manufacturers - General nearest Karyopharm Therapeutics' size, closest first, today.

Company	Price to sales ratio
KPTIKaryopharm Therapeutics	0.1×
ATNMActinium Pharmaceuticals	n/m
SPROSpero Therapeutics	1.4×
LFVNLifevantage	0.4×
Peer median	0.9×

Where Karyopharm Therapeutics ranks

What the price to sales ratio tells you

Market value divided by revenue over the last twelve months. Useful for companies with little or no profit yet, since sales are harder to make negative than earnings.

Ignores margins entirely. A software company at 10× sales with 30% margins can be cheaper than a grocer at 1× sales with 2% margins.

More on Karyopharm Therapeutics

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.